Retatrutide Before FDA Approval: What You Should Know
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Retatrutide is an experimental weight-loss drug that the FDA has not approved, which means no agency has confirmed it is safe and effective, yet a growing number of clinics are selling it anyway (CBS News). GLP Winner does not feature or recommend retatrutide since it has not yet been approved by the FDA, and this article is here to explain what is happening so you can understand the risks for yourself.
Who This Helps
This is for anyone who has seen retatrutide advertised online, anyone tempted by the eye-popping weight-loss numbers, and anyone who wants to understand why a drug being sold by licensed clinics can still be unapproved and risky. Retatrutide is investigational, meaning it is still being tested in clinical trials and has not finished the review that approved drugs must pass (ClinicalTrials.gov).
What Is Retatrutide?
Retatrutide is an experimental, once-weekly injectable that acts on three different hormone pathways at once, targeting the receptors for GIP, GLP-1, and glucagon (New England Journal of Medicine). That triple action is why it has drawn so much attention, since most current weight-loss medicines work on just one or two of those pathways. It comes from the same company behind Mounjaro and Zepbound, and retatrutide is still moving through late-stage clinical trials.
Why the Weight-Loss Numbers Are Getting Attention
In its first large human study, a 48-week phase 2 trial, adults on the highest dose of retatrutide lost about 24% of their body weight (New England Journal of Medicine). A later review of 26 trials covering more than 15,000 people without diabetes ranked retatrutide ahead of the approved options (tirzepatide and semaglutide) for expected weight loss (Annals of Internal Medicine). The most advanced study, the phase 3 TRIUMPH-1 trial, then reported an average loss of about 28% of body weight at 80 weeks, rising to about 30% at two years, with nearly half of the top-dose group losing 30% or more (Eli Lilly). Those numbers are striking, and they came from tightly controlled trials with medical supervision that online buyers do not get.
What the Trials Found About Side Effects
Across the trials, the most common side effects were stomach-related, including nausea, vomiting, and diarrhea, a pattern in line with the whole GLP-1 class (New England Journal of Medicine). Most were mild to moderate, and more people stopped treatment as the dose climbed (Eli Lilly). The drug is also still being studied for longer-term effects, which is part of what the ongoing phase 3 program is designed to measure (ClinicalTrials.gov).
Why “Not FDA Approved” Matters
The FDA approval process is the step where independent reviewers check whether a drug's benefits outweigh its risks before it can be sold (FDA). Retatrutide has not finished that process, so no regulator has signed off on the right dose, the long-term safety, or how it should be made (CBS News). Selling it for general use is barred by federal law, which is why the versions sold online exist in a legal grey zone.
What this means for you: an approved drug comes with a known dose, a verified manufacturer, and a label the FDA reviewed, and retatrutide bought online comes with none of those guarantees (CBS News).
What the CBS News Investigation Found
A CBS News investigation identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed physicians and nurse practitioners (CBS News). One 42-year-old woman reported to the FDA that she had severe vomiting, fainting, and hard lumps on her abdomen after buying the drug from an online vendor, one of nearly a dozen reports that named retatrutide as the only suspect. In one enforcement case, a state pharmacy board found that a single pharmacy had shipped 153 retatrutide prescriptions into Ohio and reached a settlement that included a $250,000 fine.
How This Is Different From Compounded GLP-1 Medications
It is easy to lump retatrutide in with compounded GLP-1 medications, but the two sit in different legal categories. A compounded GLP-1 medication is not an FDA-approved finished drug, and it should not be described as identical to the brand it is based on. What it does have is an FDA-approved medicine behind it: licensed 503A and 503B pharmacies prepare it under state board or FDA oversight, working from a drug the FDA has already reviewed and approved (FDA). Retatrutide has no FDA-approved version at all, so there is no approved medicine behind the copies being sold online. Some sellers market it as a research peptide, which is another reason buyers can lose track of what they are actually getting.
What You Can Do
If you want the kind of weight loss seen in these trials, FDA-approved medicines like Wegovy and Zepbound are available now and have completed the review retatrutide has not (CBS News). If you are comparing providers and prices for those approved options, you can use the GLP Winner survey to compare providers and pricing before you commit. When retatrutide does complete FDA review, its label and approved uses will be public, and that is the point to revisit it.
Final Takeaway
Retatrutide's trial results are genuinely impressive, and it may well earn FDA approval down the road. Right now it has not, and the versions for sale online skip the safety checks that approval is built to provide. The clinics selling it may look professional, but a licensed sign on the door does not replace a finished FDA review. Strong early data is a reason to stay interested and to wait for the full review. If you want results like these, approved options exist and your provider can help you weigh them. Staying patient here is its own kind of smart.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Lilly wants retatrutide classified as a biologic, but the FDA is not agreeing, now there is a lawsuit. What the lawsuit and OFA brief actually say.
California AB-1990 would raise ingredient, record-keeping, and advertising rules for compounded GLP-1 medications. What it could mean for you.
Retatrutide shows major Phase 3 weight-loss results but remains investigational. Learn what’s real in 2026 and why social ads can be misleading.
Categories
Curated by
